Pathology and Lab Medicine

Episodes 17-32 of 33

Maximizing Adherence and Persistence via Patient Engagement
Maximizing Adherence and Persistence via Patient Engagement
MinuteCE®
Maximizing Adherence and Persistence via Patient Engagement
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
MinuteCE®
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
MinuteCE®
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
1.25 program credits
- Nadia Harbeck, MD, PhD
1.25 program credits
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
MinuteCE®
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC
Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC
MinuteCE®
Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC
1.00 program credit
- Charu Aggarwal, MD, MPH
1.00 program credit
Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents
Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents
MinuteCE®
Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents
1.00 program credit
- Charu Aggarwal, MD, MPH
- Alexander Drilon, MD
1.00 program credit
The Role of Chemotherapy and Immunotherapy in ROS1-Rearranged NSCLC
The Role of Chemotherapy and Immunotherapy in ROS1-Rearranged NSCLC
MinuteCE®
The Role of Chemotherapy and Immunotherapy in ROS1-Rearranged NSCLC
1.00 program credit
- Charu Aggarwal, MD, MPH
- Alexander Drilon, MD
1.00 program credit
MinuteCE®
Next-Generation TKI Therapy for ROS1-Rearranged NSCLC
1.00 credit 9 episodes
- Charu Aggarwal, MD, MPH
- Alexander Drilon, MD
1.00 credit 9 episodes
Intracranial Activity of ROS1 TKIs
Intracranial Activity of ROS1 TKIs
MinuteCE®
Intracranial Activity of ROS1 TKIs
1.00 program credit
- Charu Aggarwal, MD, MPH
1.00 program credit
Case: Treatment Selection for ROS1-Rearranged NSCLC Patient with Brain Metastases
Case: Treatment Selection for ROS1-Rearranged NSCLC Patient with Brain Metastases
MinuteCE®
Case: Treatment Selection for ROS1-Rearranged NSCLC Patient with Brain Metastases
1.00 program credit
- Charu Aggarwal, MD, MPH
- Alexander Drilon, MD
1.00 program credit
First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
MinuteCE®
First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
1.00 program credit
- Alexander Drilon, MD
1.00 program credit
Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors
Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors
MinuteCE®
Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors
1.00 program credit
- Charu Aggarwal, MD, MPH
1.00 program credit
Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient
Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient
MinuteCE®
Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient
1.00 program credit
- Charu Aggarwal, MD, MPH
- Alexander Drilon, MD
1.00 program credit
Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
MinuteCE®
Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
1.00 program credit
- Alexander Drilon, MD
1.00 program credit
ASCO Investigates Disparities in Cancer Care: Representation in Oncology
ASCO Investigates Disparities in Cancer Care: Representation in Oncology
Project Oncology®
ASCO Investigates Disparities in Cancer Care: Representation in Oncology
- Jacob Sands, MD
- Lori Pierce, MD, FASTRO, FASCO
Beyond the Colonoscopy: New Screening Guidelines for Colorectal Cancer
Beyond the Colonoscopy: New Screening Guidelines for Colorectal Cancer
Project Oncology®
Beyond the Colonoscopy: New Screening Guidelines for Colorectal Cancer
- Matt Birnholz, MD